Recent presentations and scientific papers. Presentations are in Adobe Acrobat format unless otherwise noted.
Scientific Presentations
High Rate of Sustained Virologic Response in Patients with HCV Genotype-1A Infection: A Phase 2 Trial of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin (EASL, April 2014)
Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection (AASLD, November 2013)
PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety (AASLD, November 2012)
Identification and Characterization of PPI-383, a Next Generation HCV NS5B Non-Nucleoside Inhibitor with Potent Activity Against All Major HCV Genotypes (EASL, April 2012)
Dose Ranging Trial of PPI-461, a Potent New Pan-Genotypic HCV NS5A Inhibitor, in Patients with HCV Genotype-1 Infection (AASLD, November 2011)
Safety and Pharmakinetics of PPI-461 : A Potent HCV NS5A Inhibitor with Pan-Genotype Activity (AASLD, April 2010)
Resistance Monitoring of HCV Patients Treated for Three Days with the NS5A Inhibitor PPI-461 Reveals Rapid Emergence of HCV Variants (AASLD, November 2010)
Identification and Characterization of PPI-461, a Potent and Selective HCV NS5A inhibitor with Activity Against all HCV Genotypes (EASL, April 2010)
Identification and Profile of Potent and Selective Inhibitors of HS5A HCV Protein (EASL, April 2009)
